ipamorelin and cjc1295 CJC-1295 (Mod GRF 1-29) & - 10MG CJC-1295 / Ipamorelin Blend -

BPC-157: 0.25-0.5 mg daily subcutaneous TB-500: Loading phase 2.5 mg twice weekly for weeks 1-4, then maintenance 2-3 mg weekly Duration: 6-8 weeks concurrent use Note: Administer separately

However, no difference was found between the two groups when comparing changes in total glutathione levels (responders p = 0.05, non-responders p = 0.06) (Table 4)

The EPR Effect: Unique Features of Tumor Blood Vessels for Drug Delivery, Factors Involved, and Limitations and Augmentation of the Effect

At Rejuvime, all protocols are overseen by a medical provider and tailored to your individual health picture

PubMed Wang X, et al

A person should administer near the belly button area but avoid the navel itself